Dylan Van Haaften, an analyst from Stifel Nicolaus, maintained the Hold rating on Carl Zeiss Meditec (0DHC – Research Report). The associated price target remains the same with €60.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Dylan Van Haaften has given his Hold rating due to a combination of factors impacting Carl Zeiss Meditec’s outlook. The company’s guidance remains unchanged, despite an optimistic outlook for the Chinese market, particularly in refractive consumables. However, tariffs affecting manufacturing in Germany and Singapore pose challenges that prevent a more positive guidance adjustment.
Additionally, while there is an expected acceleration in the second half of the year, driven by the Chinese Visumax 800 launch and improved performance in certain divisions, there are concerns about profitability due to rising operational expenses. The upcoming CEO transition adds an element of uncertainty, especially regarding strategic clarity in the Chinese market, which remains a focal point for the company. These factors collectively contribute to the Hold rating, as the potential for growth is balanced by existing challenges and uncertainties.
According to TipRanks, Van Haaften is an analyst with an average return of -4.0% and a 38.30% success rate.